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Abstract
While elucidating the peculiar epitope of the a-PrP mAb IPC2, we found that PrPSc exhibits the sulfoxidation of residue
M213 as a covalent signature. Subsequent computational analysis predicted that the presence of sulfoxide groups at
both Met residues 206 and 213 destabilize the a-fold, suggesting oxidation may facilitate the conversion of PrPC into PrPSc.
To further study the effect of oxidation on prion formation, we generated pAbs to linear PrP peptides encompassing the
Helix-3 region, as opposed to the non-linear complexed epitope of IPC2. We now show that pAbs, whose epitopes comprise
Met residues, readily detected PrPC, but could not recognize most PrPSc bands unless they were vigorously reduced. Next,
we showed that the a-Met pAbs did not recognize newly formed PrPSc, as is the case for the PK resistant PrP present in lines
of prion infected cells. In addition, these reagents did not detect intermediate forms such as PK sensitive and partially
aggregated PrPs present in infected brains. Finally, we show that PrP molecules harboring the pathogenic mutation E200K,
which is linked to the most common form of familial CJD, may be spontaneously oxidized. We conclude that the oxidation
of methionine residues in Helix-3 represents an early and important event in the conversion of PrPC to PrPSc. We believe that
further investigation into the mechanism and role of PrP oxidation will be central in finally elucidating the mechanism by
which a normal cell protein converts into a pathogenic entity that causes fatal brain degeneration.
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Introduction
Prions are infectious agents that cause neurodegenerative
diseases, such as scrapie, bovine spongiform encephalopathy
(BSE) and CJD. They are believed to be composed mainly of
PrPSc, a misfolded form of the GPI-anchored glycoprotein termed
PrPC[1]. While the function of PrPC has not been fully elucidated, it
has been suggested that this protein plays a role in the protection of
cells from copper-induced oxidative stress [2–5]. Until recently, and
mainly in the absence of convincing data to the contrary, the two
PrP isoforms were believed to differ from each other only by their
high-order structures; mostly an a-helical fold for PrPC, and largely
a b-sheet assembly for PrPSc[6]. Nevertheless, while investigating
the epitope of an a-PrP monoclonal antibody (mAb) with an
uncommon recognition pattern (IPC2), we came to the conclusion
that at least one of the Helix-3 methionine residues of PrPSc, M213,
is differentially oxidized [7]. The oxidation of PrPSc was also
confirmed by chemical reduction experiments, state of the art mass
spectrometry and detection by an antibody generated against a
MetO rich maize protein [8]. The finding that M213 as well as the
other conserved Helix-3 Met residue, M206, were oxidized in PrPSc
was first reported in the seminal work of Stahl et al. following
sequencing of the PrP27-30 endoLysC peptides [9]. The fact that
these specific Met residues are oxidized in PrPSc is particularly
intriguing since they are the most buried residues among
methionines in the 3D PrP a-fold and thus are less accessible to
reactive oxygen species (ROS) [10]. So is the case for Met 205,
present in PrP proteins from some species, which when mutated to
both Ser or Arg destabilizes the protein structure [11]. However, if
and when they are oxidized, Helix-3 Met residues may not be
targeted by the methionine reductase (Msr) system, which reverses
oxidation of accessible Met residues [12,13]. Indeed, it was shown
that while mice overexpressing superoxide dismutase (SOD), which
inhibits oxidation, presented prolonged incubation periods upon
RML infection, ablation of the MsrA system did not reduce the time
from infection to disease outbreak [14].
The time course of Helix-3 Met oxidation as related to PrP
conformational conversion is of great mechanistic importance. If
this specific oxidation takes place after PrPSc is formed and
accumulated in brain cells, then Met oxidation, while being an
interesting covalent marker of PrPSc, may not participate in the
sequence of events leading to prion formation and disease
manifestation. Conversely, if Met oxidation occurs on the PrPC
form and mediates the subsequent conformational change, then
methionine oxidation may constitute an early and important step
in prion formation. Along these lines, theoretical investigations
have predicted that the polarity increase of Met 206 and 213
residues upon sulfoxidation may induce destabilization of the PrP
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helical conformation [15]. This prediction agrees with the
destabilization of the native a-fold and the appearance of
proaggregating properties observed in PrP chains with either
methoxinine or serine substitutions of Helix-3 Met residues
[16,17]. To further establish the role sulfoxidation in PrPSc
formation, we aimed to generate pAb antibodies against linear PrP
human/mouse sequences, which include reduced and oxidized
Helix-3 Met residues. As opposed to the complex IPC2 epitope,
which precludes simple recognition of most PrP forms upon
disulfide bond reduction [7], an antibody raised against a linear
sequence should detect all denatured PrP forms unless a covalent
modification in the amino acid chain interferes with such
recognition. Furthermore, the use of such antibodies would allow
quantitative investigation of the different PrP forms under similar
conditions, avoiding the need for distinct purification protocols,
which alone may change the properties of the tested proteins.
Consistent with this prediction, we now show that all human
PrPSc and most mouse PrPSc chains were not detected by
antibodies generated against reduced PrP Helix-3 Met residues
unless these brain proteins were previously reduced by strong
chemical reagents. In addition, our antibodies did not detect PrPSc
expressed in prion-infected cells or partially aggregated PrPs
present in gradient fractions of prion-infected brains, indicating
that both newly formed PrPSc as well as intermediate PrP forms
could be oxidized. Intriguingly, this was also the case for a PK-
sensitive mutant PrP form linked to the most prevalent familial
prion disease rHuPrP(23–231) E200K[18]. Our results establish
the presence of sulfoxides in the Helix3 methionines in all
pathogenic forms of the prion protein and indicate that such
oxidation most probably precedes the conversion of PrPC into
proteinase K (PK) resistant PrPSc.
Results
Tailoring antibodies against PrP Helix-3 epitopes
Figure 1A shows the sequences of the PrP Helix-3 region for
various species. These sequences are very similar for all species
listed and even identical for the 206–214 regions, which includes
both Met206 and Met213. Some species (such as human, mouse
and cow) also present a Met residue at position 205. To generate
specific Ab to reduced and sulfoxidized Helix-3 PrP forms, we
immunized rabbits with several KLH-coupled peptides (Figure 1B).
These peptides include KLH coupled to the Hu/Mo 203–214
sequence, which covers the three Met residues in these species. As
oxidized antigens, we inoculated rabbits with two peptides
prepared by different methods, including Hu/MoPrP 201–214
coupled to KLH, synthesized with MetO residues, and KLH-C-
204-213, which was oxidized with H2O2 after synthesis and
coupling. Following several rounds of immunization (see Meth-
ods), the rabbits (two for each peptide) were bled, and isolated
serum was tested against normal brain homogenates from different
species. Next, positive homogenates were immunoblotted with the
designated antiserum preincubated with an array of small PrP
peptides (Figure 1C) to determine the recognition site of each
antibody on the protein sequence by competition. Finally, the
characterized serum samples were tested against prion-infected
samples.
No reactivity against any form of PrP was detected using the
serum from the rabbits immunized with the oxidized KLH-KM
peptide (not shown). Properties of the other serum samples are
described in Figure 2. As shown in panel A, both the antiserum
raised against the KLH-conjugated and oxidized TC peptide (pAb
RTC) and the antiserum raised against the reduced VC peptide
(pAb RVC) clearly recognized Mo and Hu PrPC, although they
did not recognize Ha and Bo PrPs. Indeed, while the Mo and Hu
PrP sequences are identical in this region, other species present
slight individual differences in the 203–205 sequence (Figure 1a).
As opposed to the similarity in species reactivity of the pAbs
RTC and RVC, the RTC and RVC epitopes on the PrP sequence
were found to be different, as determined by the inhibition of the
PrP immunoblotting signal with an array of peptides. While the
activity of the pAb RVC was inhibited by the KM peptide, which
includes the three Met residues, this same peptide did not affect
recognition of PrP by the pAb RTC in either the reduced or
H2O2-oxidized form. In contrast, the activity of RTC was
inhibited by the TM peptide (201–205), suggesting that this pAb
recognizes the TVDK or TVDKM sequence (present in Hu and
Mo PrP), N-terminally to the relevant Met residues. This finding
implies that both oxidized PrP peptides failed to generate an
immune response to the oxidized Met rich region, consistent with
investigations in other fields indicating that charged and oxidized
epitopes are mostly unrecognized by T-cell receptors [19,20].
Antibodies designed to recognize Helix 3 Met residues
may not recognize PrPSc
Next, we examined the capacity of the RTC and RVC pAbs to
recognize PrPSc forms. To this effect, we immunoblotted brain
samples from normal and prion infected brains (digested in the
presence or absence of proteinase K at 37uC) with a panel of
antibodies generated against PrP epitopes upstream and down-
stream of the helix 3 Met area to ensure that PrPSc was present in
its full length under these conditions. Figure 2C shows that the a-
PrP mAb 6H4 (Prionics), which recognizes PrP in all species (at
residues 145–152), the pAb RTC and also the recombinant R1
antibody (at residues 225–231 in rodent PrP [21]) detected PrP
isoforms in normal and prion-infected brain samples. However,
the PrP recognition pattern of the pAb RVC was significantly
different. While this reagent recognized PrP from normal brain
samples as well as from undigested brain samples of RML-infected
mice and genetic and sporadic CJD patients (believed to comprise
both PrPSc and PrPC) the pAb RVC could not detect all of
Author Summary
The protein only theory, a widely accepted model
describing the prion agent, assumes that the mechanism
underlying prion disease pathogenesis includes a confor-
mational change of the a-helix rich, soluble and protease
sensitive PrPC into an aggregated and protease resistant b-
sheet rich PrPSc form. Until recently, no covalent modifi-
cation was known to be associated with such a conversion,
making it difficult to follow the individual fate of each PrP
form or to associate cellular events as stress-response or
inflammation with the formation of prions. We now show
that before PrPC initiates its conversion from proteinase K
sensitive to resistant and from soluble to aggregated in
the pathway to becoming PrPSc, it first undergoes
oxidation of the most hidden Met residues located in a
protein region exhibiting sequence identity for all species.
While the cellular events promoting such oxidation in this
transmissible disease remain unclear, we present evidence
that PrP molecules carrying a mutation ascribed to the
most common familial prion disease spontaneously
oxidizes at these same Met residues. Our data provide
new insights into the mechanism underlying familial
Creutzfeld Jacob disease (CJD) and contribute to our
general understanding of the fundamental processes
related to prion pathogenesis.
Oxidation Of Met Residues in PrP
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HuPrPSc and detected only low levels of MoPrPSc after PK
digestion.
To confirm that the recognition pattern of the pAb RVC vis a
vis proteinase K resistant PrPSc forms indeed resulted from Met
oxidation, we subjected PK digested extracts from prion-infected
human and mouse brains to N-methylmercaptoacetamide (MMA),
a specific MetO reducing agent [22]. Figure 2D shows that
following MMA treatment, the pAb RVC easily recognized both
human and mouse PrPSc at detection levels similar to those of the
a-PrP mAb 6H4 both before and after MMA treatment. Similar
but less striking results were obtained for detection of the reduced
samples by IPC2 because, as described in our previous publication
[7], full detection of reduced PrP forms by this mAb requires
deglycosylation of PrP forms by PNGase.
Oxidation of newly formed PrPSc
To establish whether oxidation of Met residues is essential for
the conversion of PrPC to PrPSc, we asked whether Met oxidation
occurs first on PrPC or whether oxidation is a delayed effect related
to the long-term accumulation and reduced clearance of
proteinase K resistant and misfolded prion protein in the brains
of the affected subjects. To separate these mechanistic possibilities,
we studied by pAb RCV the oxidation status of newly formed PK
resistant PrPSc generated in cells permanently infected with prions,
such as ScN2a [23] and ScGT1 cells [24]. Since these cells
constantly proliferate, PrPSc produced by them can be considered
relatively new, as opposed to the PrPSc molecules that accumulate
in infected brains.
For this experiment, extracts from ScN2a cells (infected with the
RML mouse prion strain) and from the ScGT1 cell line (infected
with both the RML and the 22L prion strains) [25] were treated in
the presence or absence of proteinase K and immunoblotted with
the anti-PrP IPC1mAb, which recognizes all forms of Mo and Ha
PrP ([7], Sigma), and the pAb RVC, which properties were
described above. Extracts from the uninfected cell lines (N2a and
GT1) and brain samples from normal and scrapie-infected mice
were included in this study. Figure 3a shows that while the IPC1
mAb recognized all forms of PrP in cells and brains, the pAb RVC
failed to detect proteinase K resistant PrP forms in any of the
infected cell systems and barely detected bands characteristic for
PrPSc before proteinase K digestion. These results indicate that
newly made PrPSc may be quantitatively oxidized, as was shown
here for PrP from two different cell lines and for two prion stains
(ScN2a-RML, ScGT1-RML and ScGT1- 22L). Similar results
were obtained for an RML infected GT1 line expressing chimeric
Mo-Ha PrP [26,27] (not shown here for the pAb RVC, see bellow
for a similar antibody). Contrary to PK resistant PrPSc in the cells,
and as depicted also in Figure 2, pAb RVC could detect low levels
of PrPSc in infected mouse brains as well as some prion-related
bands in the undigested parallel samples. Therefore, we conclude
that in infected murine brains, as opposed to infected human
brains or infected mouse cells, low levels of proteinase K resistant
PrP are present in a fully or partially reduced form. Whether such
PrPSc molecules are formed independently or join a seed of
oxidized PrPSc molecules after formation is currently unknown.
Similar to brain PrPSc, detection of cell PrPSc by the pAb RVC
could be restored in both cell lines when samples were reduced by
MMA before being subjected to immunoblotting (Fig. 3B). This
finding is consistent with the notion that the lack of PrPSc
recognition by RVC indeed relates to the oxidative state.
Met oxidation of intermediate PrP states
Previous studies on prion-infected cells demonstrated that the
formation of PrPSc from PrPC is a slow multistep process, which
may include a variety of intermediate PrP states [28,29]. To
investigate whether PrP Helix-3 Met oxidation occurs before the
acquisition of PK resistance, we examined the oxidation state of
putative PK sensitive intermediate forms. Several experimental
approaches indicated the presence of such intermediates, denom-
inated either PrPSc-sen (from PK sensitive) or PrP* [30–32]. While
Figure 1. Helix-3 sequences. (A) Helix-3 sequences in different PrP species. The 206–214 region, comprising M206 and M213, is completely
conserved in all species. (B) PrP peptides used for the generation of a Helix-3 antibodies. (C) PrP peptides used for the inhibition of a Helix 3
antibodies.
doi:10.1371/journal.ppat.1000977.g001
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these forms were never proven directly to be infectious, they were
shown to present characteristic PrPSc properties. Intermediate PK
sensitive PrP forms may be present as aggregates and require
extensive or partial denaturation to be recognized by anti-PrP
antibodies, as is the case for PrPSc [33]. To determine the
oxidation state of intermediate forms of PrP, we subjected Sarkosyl
extracted control and prion-infected brain samples from murine
and human subjects to sucrose gradients, as previously described
for PrP* [30]. Fractions of the centrifuged gradients (light to heavy)
were collected and digested in the presence or absence of PK
before immunoblotting with either the mAb 6H4 or pAb RVC. As
shown in Figure 4, while PrP was similarly detected by both
antibodies in the lighter gradient fractions of control samples
(normal mouse and normal human brains), immunoblots of the
prion-infected samples (RML infected mouse and CJD E200K
heterozygous familial cases) with each of the antibodies showed
very different results. Before proteinase K digestion, PrP was
recognized by mAb 6H4 in most fractions of both human and
mouse gradients, although the banding pattern of the protein
resembled PrPC in the lighter fractions (1–3) and PrPSc in the
heavier fractions. After proteinase K digestion, only the heaviest
gradient fractions (mostly fractions 9–10) presented any form of
PrP signal, indicating that while proteinase K resistant PrPSc is the
most aggregated, partially aggregated PrP-sen forms (fractions 4–
7) may also present the PrPSc banding pattern [22]. In contrast,
when the undigested gradient fractions from the prion-infected
brains were immunoblotted with the pAb RVC, the pattern of PrP
recognition mostly resembled that of the normal brain homoge-
nates. No PrP forms were detected in any of the intermediate or
heavy fractions, except low levels of mouse PrPSc in the heaviest
fraction. Following proteinase K digestion, the PrP signal mostly
disappeared form all infected fractions, except traces in the last
fraction of the mouse gradient, consistent with the experiments
described in Figures 2 and 3. Similar results were obtained for
brain samples from sporadic CJD patients (data not shown). Since
the lack of recognition of PrP by the pAb RVC in the intermediate
Figure 2. Testing for the activity of anti-Helix-3 antibodies: pAb RVC does not recognize PrPSc generated in prion infected brains.
(A) Activity of pAb RVC and RTC, as compared to the established mAb 6H4, against normal brain homogenates from bovine, mouse, humans and
hamster. (B) Human and mouse normal brain homogenates were immunoblotted with pAb RVC and RTC alone or in the presence of diverse Helix-3
PrP peptides (see Figure 1C for the peptide sequences) (C) Brain homogenates from mice, hamster and humans (normal, prion-infected and prion-
infected digested with proteinase K), were immunoblotted with mAb 6H4, with pAb RTC or RVC, or with rec Ab R1. D) Mouse scrapie (RML) and
human CJD brains (E200K) were digested with PK, processed for MMA reduction as described in the methods and immunoblotted with a PrP mAb
6H4, IPC2, or pAb RVC.
doi:10.1371/journal.ppat.1000977.g002
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gradient fractions indicates that PrPSc-sen forms are as oxidized as
the PrPSc-res forms, we conclude that oxidation of PrP
accompanies the conformational change required for PrP
aggregation and precedes the acquisition of proteinase K
resistance during PrPSc formation. The fact that the low levels of
reduced mouse PrPSc were detected by PVC only in the most
aggregated fraction, both before and after PK digestion, further
suggests that non-oxidized mouse PrP may join the prion seed
following its formation from oxidized PrP molecules.
Spontaneous oxidation of proteinase K sensitive E200K
PrP
Figure 2C shows that as opposed to PrPC in normal human
brains and undigested PrP in the brains of sporadic CJD patients,
PrP was poorly detected in brains of heterozygous E200K PrP
fCJD patients [18]. This finding indicates that the mutant E200K
PrP molecules may be oxidized in these brains even in their initial
conformational state. Indeed, the Met rich area of PrP Helix-3 is
located C-terminally to the residue 200, which mutated form,
Figure 3. pAb RVC does not recognize PrPSc generated in prion infected cells. (A) Brain (normal, scrapie infected, as well as scrapie infected
digested with PK) as well as normal and prion-infected cells, (N2a and GT1 infected either with the RML or the 22L prion strains) were extracted and
immunoblotted with mAb IPC1 as compared to pAb RVC. (B): Effect of the MMA chemical reduction of proteinase K digested ScGT1 and Sc N2a cells
on the PrP recognition by mAb IPC1, mAb IPC2 and pAb RVC.
doi:10.1371/journal.ppat.1000977.g003
Figure 4. Intermediate PrP forms are oxidized as PrPSc. Sarkosyl extracted brain samples from normal and prion infected mice and humans
were subjected to sucrose gradient centrifugation. Fractions from these gradients were digested in the presence or absence of proteinase K and
immunoblotted with both mAb 6H4 and pAb RVC.
doi:10.1371/journal.ppat.1000977.g004
Oxidation Of Met Residues in PrP
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E200K, is the most abundant among familial CJD patients. In
fact, peptides embracing this region and comprising either E
(peptide 195–213) or K (peptide 185–205) at position 200 were
used more than a decade ago for the generation of specific (to wt
or mutant) anti- PrP pAbs [34]. The pAb raised against the HuPrP
peptide containing E at position 200 (designated in Figure 1b as
the pAb RGM) did not recognize proteinase K sensitive PrP forms
expressed in fibroblasts from homozygous E200K patients,
suggesting that the pAb RGM specifically detected wt PrP as
opposed to the mutant E200K form [34]. Next, brain extracts
from heterozygous CJD E200K patients were immunoblotted with
this antiserum. The results showed convincingly that the pAb
RGM did not detect proteinase K-resistant PrP forms. Due to the
general belief at the time that no covalent modification separates
PrPC from PrPSc and that the only difference between the mutant
and wt PrP proteins could be the mutation itself, it was concluded
that in heterozygous E200K patients only the mutant protein (K at
codon 200) acquires the proteinase K resistance property during
disease [34]. This conclusion was then generalized using other
methods and additional PrP mutations [35].
Based on the results described above for the pAb RVC,
demonstrating that antibodies directed against Helix-3 methio-
nines may not recognize PrPSc and since the peptide used for
generation of the RGM antibody comprised both the 200 residue
and the Helix-3 methionines, we now investigated whether this
reagent does not recognize E200K PrPSc specifically or otherwise
cannot detect all forms of human PrPSc, as described above for
pAb RVC. To this effect, we immunoblotted brain homogenates
from RML infected-mice as well as from sporadic or familial
E200K CJD human cases and analyzed them in parallel with both
anti-PrP mAb 6H4 and pAb RGM. As depicted in Figure 5a, pAb
RGM, similarly to pAb RVC, did not recognize proteinase K
resistant HuPrP in both sporadic and E200K familial CJD
samples, and in addition detected poorly undigested forms of
HuPrP E200K. Consistent with the results obtained with pAb
RVC, pAb RGM detected low levels of MoPrPSc from infected
brains, but did not detect PrPSc from infected cells lines, as
depicted here for GT1 cells expressing chimeric Mo-Ha PrP.
Similar results were obtained for PrPSc from ScN2a cells (not
shown).
To assess whether pAb RGM has separate recognition sites for
E at position 200 and for the Helix 3 Met residues, which may
explain why this antibody did not detect 200K PrP in fibroblasts
from E200K homozygous subjects [34], we repeated the inhibition
experiments described for RTC and RVC in Figure 2 using pAb
RGM. We found that the activity of pAb RGM, which detected
Figure 5. HuPrP E200K is spontaneously oxidized. (A) Brain samples from scrapie infected mice and from humans suffering from familial E200K
or sporadic CJD, were digested in the presence or absence of proteinase K and subsequently immunoblotted with mAb 6H4 or pAb RGM. The last 2
lanes of each gel comprise normal GT1 and proteinase K digested ScGT1 cells expressing a chimera Mo/Ha PrP form. (B) Human and mouse normal
brain homogenates were immunoblotted with the RGM antibody alone or preincubated with several PrP peptides in the Helix-3 Met area. (C)
Immunoblots of HuPrP(23–230) wt and E200K with 3F4 (recognizing the 109–112 region), DZS18 (recognizing oxidized Met residues in different
proteins), IPC2 (recognizing non-oxidized M213) and RGM (recognizing non-oxidized M206). Blots were prepared in the absence of b-
mercaptoethanol. (D) Thermal stability of HuPrP(23–230) wt and E200K probed by the relative change in the ellipticity at 220 nm as a function of
temperature. Insert: Far-UV CD spectrum of HuPrP(23–230) wt and E200K.
doi:10.1371/journal.ppat.1000977.g005
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only mouse and human PrP (not shown), was totally inhibited by
several peptides covering the Helix-3 Met residues, including the
one comprising the 203–211 PrP sequence. This prevents the
residue at codon 200, regardless E or K, from forming part of the
pAb RGM epitope (Figure 5b), indicating that the lack of
recognition of the mutant PrP by pAb RGM is not related to
the presence of K instead of E at position 200. In addition, and
since the epitope of this antibody does not comprise M213, these
results constitute the first direct evidence that oxidation of M206
(and/or M205) can also be considered as a covalent signature of
PrPSc, as predicted by the theoretical studies.
To investigate why pAb RGM was unable to recognize the
mutated PrP even though its epitope does not include the 200
residue, we examined the recognition of wt and rHuPrP E200K by
RGM as well as by a panel of antibodies designed to detect
oxidized and non-oxidized PrP forms. As shown in Figure 5C,
while a-PrP mAb 3F4 recognized the wt and mutant rHuPrP
chains equally, pAb RGM did not detect the mutant recombinant
protein, as described before for mutant PrP expressed in fibroblasts
from E200K homozygous patients [34]. Similar results were
obtained when wt and mutant recombinant PrPs were immuno-
blotted with a-PrP mAb IPC2, the epitope of which includes Met
213 and the adjacent disulfide bond, both distant from the site of
the E200K mutation. In contrast, only the rHuPrP E200K was
recognized by pAb DZS18, a pAb raised against a MetO rich
maize repetitive sequence, which was shown to recognize enriched
PrPSc as well as other oxidized proteins [8]. These results suggest
that Helix-3 methionines in PrP E200K may undergo facilitated or
spontaneous oxidation both in cells [34] and in its a-folded
recombinant form. Indeed, Figure 5D shows that the monomers of
wt and E200K HuPrP (23–231) are indistinguishable by far-
ultraviolet CD spectroscopy at 25uC and pH 4.5, but they differ in
their thermal denaturation profile. Curve fitting yielded Tm values
of 6060.5uC and 54.561uC for the wt and E200K chains, which
agrees with previously reported destabilization of this mutant PrP
under a different setup [36]. These results, as well as previous
experiments showing charged-induced alterations of E200K PrP
[37] suggest that changed dynamics of Helix-3 in the mutated
protein might favor transient exposures of the contained
methionines to ROS. The spontaneous oxidation of E200K PrP
also explains the poor recognition of undigested PrP from E200K
patients brain by both RGM and RVC pAbs (Fig. 2, 5).
Discussion
We have shown here that antibodies generated against reduced
Helix-3 PrP Met residues could not recognize the majority of
PrPSc forms. This finding applied to most PrPSc accumulated in
scrapie-infected mouse brains and for all PrPSc accumulated in
human CJD brains, as well as for all newly formed PrPSc in several
prion-infected cell lines. Since reduction by MMA restored the
recognition of brain and cell’s PrPSc by these antibodies, we
conclude that most Helix 3 Met residues in PrPSc, both as newly
made in cells, or as long term accumulated in infected brains are
oxidized. Our results also indicate that Met oxidation is also
present in intermediate PrP forms, such as proteinase K sensitive
and partially aggregated PrPs found in human and mouse infected
brains, indicating that oxidation accompanies aggregation and
precedes acquisition of proteinase K resistance by the nascent
PrPSc molecules. In addition, we show here that pathogenic
mutant PrP forms, as is the case for E200K PrP [18], are mostly
oxidized even in the monomeric state. Taken together, our results
are consistent with the conclusion that Helix-3 Met oxidation is an
early event in the conversion of PrPC into proteinase K resistant
PrPSc and thus in prion formation and subsequent disease
pathogenesis.
From a structural point of view, Met oxidation involves the
transformation from a moderated hydrophobic to a hydrophilic
side chain. While in protein exposed residues this chemical change
may not have major structural effects, sulfoxidation of buried Met
may impact the stabilization interactions maintaining the proteins
3D fold. Indeed, this intuitive prediction is in agreement with our
theoretical studies, which showed that changing the sulfur atom of
Met206 and M213, both single or in combination, by a sulfoxide
destabilizes the native a-folded [15], thereby allowing for a
conformational conversion. Indeed, increasing the polarity side
chain at any of the conserved Helix-3 Met residues (Met205,
Met206 and M213) impedes the native state folding and the
appearance of proaggregating states [11,16,17,38,39]. Then, from
these studies it can be proposed that the tolerance for the PrP a-
fold is determined by the redox state of the Helix-3 Met residues
and that the intolerance for the native state increases the
probability of the productive conversion pathway.
Surprisingly, our results suggest that raising antibodies specific
for PrPC is not a difficult task. The Met rich area in Helix-3
appears to be quite immunogenic, as deduced by the fact that even
immunization of rabbits with the relatively large peptide spanning
amino acids 195–213 yielded antibodies against the Met rich area
(see Figure 6). So was the case for the mAb IPC2, which was
produced following the immunization of mice with full length
recombinant mouse PrP [7]. Reagents similar to pAb RGM and
RVC may have been produced in many laboratories, but their
true meaning not understood. In contrast, raising antibodies
against oxidized PrP peptides that may be specific for proteinase K
sensitive and resistant forms of PrPSc has been unsuccessful thus
far. This difficulty may relate to the well-established immunolog-
ical barrier that precludes recognition of oxidized peptides by T-
cell receptors [19,20]. Such immunological phenomena may
partially explain the apparent lack of immune response against
PrPSc in all species.
While the failure of our antibodies to recognize aberrant forms
of mouse and human PrP was mostly quantitative, a recent MS
study failed to detect high levels of Met213 oxidation in hamster
PrPSc [40]. Indeed, while MS may be the method of choice to
establish the presence of covalent modifications in proteins, its use
for quantification of oxidation in this specific case may be limited.
First, the labile character of sulfoxidation of Met residues does not
allow for accurate separation of in vivo and in vitro modifications
[41]. Furthermore, as opposed to detection of full length mature
proteins by specific antibodies, MS detection operates on soluble
peptides produced by proteolysis, each of which has different
recovery pattern efficiencies, even in the same protein. Indeed, it
was previously shown that recovery of the PrP tryptic peptide
including M213 is quite poor, and that the recovery is even less
efficient for the peptide including M206 [42]. In this study, we
Figure 6. Scheme of Helix 2 and 3 of PrP including epitopes of
a Helix 3 antibodies.
doi:10.1371/journal.ppat.1000977.g006
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were unsuccessful in recovering the Helix3 area of HuPrP (23–
230) E200K for MS analysis, likely because the mutation, which
adds a digestion site for trypsin, generated labile peptides that
could not be identified with significant yield. Eventhough, and
given the right conditions, we assume that a combination of
immunological reagent sand MS are the right methods to look for
modifications in this and other proteins.
We also describe in this study how an antibody believed to
detect E at codon 200 of wtPrP actually recognized a reduced Met
Helix-3 sequence [34]. The reason for such misconception was
that, if, as generally believed, no covalent modifications separated
between the different forms of PrP, than the epitope of an antibody
that recognizes wt PrP (E at codon 200) but not mutant PrP (K at
codon 200) should include E at codon 200. We have shown here
that despite the accuracy of the old results, the previous
interpretation, suggesting that only mutant PrP converts into
proteinase K resistant PrP in the brains of heterozygous patients
may be mistaken in view of our new knowledge. While pAb RGM
indeed did not detect PrPSc in brains from heterozygous E200K
CJD patients (Figure 5), similar results were obtained for PK
resistant PrPSc in brains from sporadic CJD patients, which
comprise E at position 200. In addition, our results suggest that
pAb RGM did not recognize E200K PrP in cells from
homozygous subjects not because it carries K at codon 200, but
because this mutant PrP form may be present in an oxidized form,
as shown here for rHuPrP E200K. Most importantly, the finding
that E200K PrP can undergo spontaneous oxidation at Helix-3
Met residues constitutes the first mechanistic clue explaining the
late onset spontaneous appearance of CJD in carriers of
pathogenic PrP mutations. Once oxidized, the conformation of
the mutant PrP may be irreversibly impaired. We speculate that
oxidative events may facilitate spontaneous CJD outbreaks in
subjects carrying designated PrP mutations, as is the case for
E200K mutation carriers. Indeed, the prevalence of familial CJD
increases with age [43,44], as in the case for oxidative insults [45].
Whether oxidized mutant PrP can serve as a template for wt PrP
conversion in heterozygous cases remains to be established.
While our results suggest that the oxidation of PrP forms may
play a role in the formation of PrPSc, we have still to elucidate the
conditions, kinetics and mechanism that lead to the initial
irreversible oxidation of wt PrP Helix 3 Met residues. Interestingly,
it has recently been shown that when fibrillar assemblies of
recombinant PrP chains are annealed (by heat), they can transmit
prion infectivity to wt animals [46], a result that could not be
obtained with other recombinant PrP preparations [47]. It would be
interesting to test whether synthetic prions as well as prions arising
from diverse PMCA protocols [48–50] include oxidized PrP forms.
Based mainly on the fact that PrP ablated mice did not suffer
from severe neurological damage [51], it was generally assumed
that the function of PrPC is not associated with prion disease
pathogenesis. However, we show here that oxidation of Met
residues on PrPC, which may relate to its proposed antioxidative
function [5], may be an essential step in acquisition of the aberrant
PrPSc conformation. In fact, the association between oxidative
stress and PrP conversion may link the activity of the prion
proteins with other neurodegenerative conditions affected by stress
and oxidation, such as ALS, AD and Parkinson’s diseases
[2,52,53], as well as to normal aging [45].
Materials and Methods
Ethical statement
Animal experiments were conducted under the guidelines and
supervision of the Hebrew University Ethical Committee, which
approved the methods employed in this project. Brain human
samples were received following postmortem examinations from
the Pathology Department of the Hadassah University Hospital.
Immunobloting analysis, as that described in this manuscript (in
search of PrPSc), is part of the routine pathological protocol
applied on brains from suspected CJD cases. Our laboratory in the
Hadassah Department of Neurology is the national referral center
for CJD diagnosis (genetic and biochemical testing). The testing of
these samples was approved by both the safety and ethical
authorities of the Hadassah University Hospital. Since all cases of
CJD and alike negative controls are unable to sign for such tests
long before their death due to their medical condition, the relatives
of these patients provided informed written consent for PM
studies. Enabling close relatives to provide such consent is the
standard policy of the Israeli Ministry of Health.
Peptide and protein productions
PrP peptides were synthesized on a Liberty peptide synthesizer
with a Discover single mode microwave module, using standard
Fmoc chemistry. Amino acids were purchased from Luxembourg
Bio Technologies, except for Fmoc-Met(O)-OH, which was
purchased from Novabiochem. Peptides were cleaved from the
resin by treatment with a mixture 95% trifluoroacetic acid, 2.5%
water, 2.5% triisopropylsilane, and precipitation with cold
diethylether. The peptides were purified on a Vydac C8
semipreparative column using gradients of 5% to 60% acetonitrile
in water, with 0.1% trifluoroacetic acid (TFA) in both solvents.
The mass of the peptides was measured using an Applied
Biosystems Voyager-DE Pro MALDI TOF mass spectrometer
and verified to be within 61 Da of the theoretical mass. The
purified peptides were lyophilized with 30% acetic acid to remove
residual TFA.
Recombinant HuPrP(23–230) wt (with M129) and E200K
chains were produced, purified and refolded into the a-form from
their pET11a constructs using oxidized glutathione for disulfide
bond formation and including 2 mM Met in refolding buffers
[54,55]. The mutant chain was generated by site-directed
mutagenesis using QuickChange protocols with the following
primers: 59-GAAGTTCACCAAGACCGACGTTAAG-39 (for-
ward) and 59–CTTAACGT CGGTCTTGGTGAACTTC-39
(reverse). Before their use, proteins were equilibrated by dialysis
in 10 mM NaAc pH 4.5 containing 50 mM NaCl and 0.5 mM
citrate and characterized both as monomers by dynamic light
scattering using DynaPro Titan spectroscatter (Wyatt Technolo-
gy). CD spectra were recorded using a Jasco-810 spectropolarim-
eter operating at 25uC, and using 0.1 cm pathlength cuvettes and
about 13 mM protein concentration solutions. Thermal denatur-
ation experiments were performed by following the changes in the
ellipticity at 220 nm as the samples were heated from 15uC to
85uC at the rate of 1 degree/min.
Generation of a-PrP pAb
Designated PrP peptides were coupled to activated KLH
(Sigma) and inoculated into rabbits while emulsified into Complete
Freund’s Adjuvant for the first immunization and Incomplete
Freund’s Adjuvant for subsequent injections. Most peptide
immuniziations were performed at the animal facility of the
Hebrew University-Medical School, except the ones for the RVC
antibody which was produced by GenScript Inc (NJ, USA). KLH
coupled with the Cys-KM peptide was first oxidized with 20 mM
H2O2. After 15 min incubation at 37uC, the reaction was
quenched by addition of 20 mM of free methionine before
addition to the adjuvant. Following 3 lines of immunization, serum
samples from all immunized rabbits were tested for their anti-PrP
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activity. Rabbits with positive sera were immunized once again
before final collection of blood. Antisera were purified by affinity
chromatography, using for retention either peptides (RVC
antibody) or Protein A (RTC and RGM antibodies).
Tissue sources and brain homogenate preparation
Brain samples of normal humans and patients with confirmed
sporadic and genetic E200K CJD were obtained from Hadassah
University Hospital Pathology department. Brains from mice
infected with the RML scrapie prions and from golden hamsters
inoculated with Sc237 prions were provided by the Animal Facility
of the Hebrew University-Medical school. Brain homogenates
(10% w/v) were prepared by repeated extrusion through an 18-
gauge followed by a 21-gauge needle in phosphate-buffered saline
(PBS), aliquoted and maintained at 270uC until use.
Cell lines
Naı̈ve and scrapie infected ScN2a[23] and ScGT1 cells [24]
were washed, collected and lysed in 1 ml lysis buffer (100 mM Tris
pH 7.4, 100 mM NaCl, 1% NP40, 1 mM EDTA) for 10 min.
Samples were then centrifuged at 2000 rpm for 15 min at 4uC,
and the supernatant was concentrated by methanol precipitation.
Pellets were resuspended in 2% sarkosyl/STE buffer (10 mM
Tris–HCl, pH 7.5, 10 mm NaCl, 1 mM EDTA). Protein content
was determined by a BCA kit (Pierce). Equal amounts of protein
were treated in the presence and absence of 40 mg/ml proteinase
K for 30 minutes in 37uC. Digestion was stopped by the addition
of a protease inhibitor complex (Complete Protease Inhibitor
Cocktail Tablets, Roche) before subjecting the samples to
denaturation by boiling in the presence of sample buffer. Samples
were then immunoblotted with the designated anti-PrP antibodies.
Immunoblotting experiments
Normal and prion-containing brain samples were homogenated
at 10% (W/V) in 10 mM Tris, pH 7.4 and 0.3 M sucrose.
Proteinase K digestions were performed by incubating 30 ml of
10% prion-infected brain homogenates with 2% sarkosyl for
30 min at 37uC with 40 mg/ml protease. Control samples were
incubated at 37uC in the absence of proteinase K). After boiling in
sample buffer, samples were subjected to SDS PAGE and
immunoblotting with the diverse anti-PrP antibodies. For the
inhibition experiments, nitrocellulose sheets comprising the
transferred proteins were subjected either to a 1:2000 dilution of
the designated antibody alone or preincubated for at least 2 hours
with the appropriate synthetic peptide (2 mg/ml). Immunoblots
were developed with a mouse or a rabbit antibodies AP or HRP-
conjugated secondary antibodies (Promega, Madison WI).
N-methylmercaptoacetamide reduction
Proteinase K digested prion-infected cells or brain homogenates
were treated with 6 M N-methylmercaptoacetamide (MMA) [22].
After 15 h of incubation at 37uC, samples were precipitated with 9
volumes of methanol (1 h, 280uC) and then centrifuged
(10000 rpm, 30 min, 4uC). Pellets were washed twice with
methanol and processed for SDS-PAGE analysis. When immu-
noblotting with IPC2, sample buffer was devoid of b-mercapto-
ethanol [7].
Sucrose gradient centrifugation experiments
Sarkosyl extracted brain extracts from human and mouse
(normal and prion infected were subjected to a sucrose gradient as
previously described [30]. Shortly, 140 ml of 10% brain homog-
enates (mouse:normal and scrapie infected; human: normal and
CJD), extracted in the presence of 2% Sarkosyl were overlaid on a
sucrose gradient composed of layers of increasing concentrations
of sucrose (10–60%). Gradients were then centrifuged for 1 h at
55000 rpm in a Sorval mini-ultracentrifuge and subsequently 11
samples of 120 ml were collected from the top to the bottom. In the
prion infected gradient fractions were digested in the presence and
absence of 40 mg/ml proteinase K before immunobloting with
either a PrP mAb 6H4 or pAb RVC.
Accession numbers/ID numbers
Human Prion Protein: P04156 (PRIO_HUMAN), Mouse Prion
Protein: P04925 (PRIO_MOUSE), Hamster Prion Protein:
P04273 (PRIO_MESAU).
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